AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03066466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: IV medication given to prevent graft versus host disease in bone marrow transplant.
Study NCT03066466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: IV or Oral medication given to prevent graft versus host disease in bone marrow transplant.
Study NCT03066466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: IV or Oral medication given to prevent graft versus host disease in bone marrow transplant.
Study NCT02304770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolaevulinic acid photodynamic therapy
Description: Aminolaevulinic acid mediated photodynamic therapy
Study NCT02334046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in elderly patients (65-80 years) .
Study NCT02334046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in adult patients (20-60 years) .
Study NCT02334046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia was maintained with sevoflurane with 1.5-2.0 vol% in air/50%oxygen mixture, and sevoflurane was adjusted to about 1.0 vol% 10 min before end of surgery.
Study NCT02334046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia was maintained with sevoflurane with 1.5-2.0 vol% in air/50%oxygen mixture, and sevoflurane was adjusted to about 1.0 vol% 10 min before end of surgery.
Study NCT03562676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weightlessness
Description: parabolic flight
Study NCT00716365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemCon bandage
Description: 5 cm X 5 cm
Study NCT00451191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin type A (BoNT/A)
Description: 100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.
Study NCT01605370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol 2.5 mg once daily
Study NCT01605370 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metoprolol succinate
Description: Metoprolol succinate 50 mg once daily
Study NCT01580696 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster
Description: 100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above.
Study NCT01580696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-vaccine clinically matched control group
Description: HLA-A2-negative patients or HLA-A2-positive patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression. No experimental treatment will be administered to this group.
Study NCT01580696 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster
Description: 500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above.
Study NCT01580696 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster
Description: 1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above.
Study NCT01580696 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster
Description: 100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above.
Study NCT01580696 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E39 peptide (500mcg)/GM-CSF vaccine plus J65 booster
Description: 500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above.
Study NCT01580696 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E39 peptide (1000mcg)/GM-CSF vaccine plus J65 booster
Description: 1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above.
Study NCT01929551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mango puree and pear juice beverage
Description: Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
Study NCT01929551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Commercial mango juice
Description: Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
Study NCT01929551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fresh natural mango
Description: Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
Study NCT01929551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Frozen natural mango
Description: Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
Study NCT01929551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Processed natural mango pulp
Description: Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
Study NCT01929551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mix of natural mango and pear
Description: Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
Study NCT01929551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 50 grams glucose load
Description: Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
Study NCT00227591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally (PO)
Study NCT00227591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study NCT00227591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03455842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-089, 162 mg, s/c, qw
Description: Subcutaneous injections of anti-IL6R every week
Study NCT03455842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-089, 162 mg, s/c, q2w
Description: Subcutaneous injections of anti-IL6R every other week
Study NCT03455842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous injections of placebo every week, until week 12. Thereafter subcutaneous injections of anti-IL6R every other week
Study NCT02341482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm
Study NCT02341482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered as specified in the treatment arm
Study NCT04980196 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: urodynaemic studies
Description: The Urodynamic studies carried out were : uroflowmetry and cystometry. The Uroflowmetry was performed by the gravimetric method Detrusor over activity was diagnosed when the patient has involuntary detrusor contractions during filling with or without leakage which may be spontaneous or provoked,
Study NCT03986216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReIn-Hand device assisted home-based practice
Description: Practice reach-grasp-retrieve-release at home with the aid of ReIn-hand device
Study NCT01886105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sm-EDTMP
Description: Subjects receive a tracer infusion of Samarium-153 EDTMP at 1 mCi/kg. 3D dosimetry using SPECT images are obtained post tracer infusion to determine the distribution of dose delivered to the tumor and surrounding normal tissues. Tracer activity will be applied to development of the external beam radiation (EBT) planning. Second treatment infusion of Samarium will then be implemented. Maximum activity administered will be 30 mCi/kg.
Study NCT01886105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Infusion
Description: Administered 14 days after Treatment infusion of Samarium-153 EDTMP.
Study NCT01886105 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Description: The radiotherapy portion of the combined plan will be delivered according to the judgement of the treating radiation oncologist. The total dose to be used will be modified based on surrounding tissue tolerances as evidenced by Samarium infusion and SPECT image planning.~After the treatment infusion, SPECT scans will again be performed to confirm the total dose delivered and subsequently adjust the EBT portion of the treatment plan, as necessary.
Study NCT03445325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LiGHT v2.1
Description: The LiGHT mobile program strives to support youth and their families to adopt lifelong healthy behaviours in four areas - eating, physical activity, recreational screen time and sleep - to foster healthy growth and development, to prevent chronic diseases and manage unhealthy weights.~The program includes content that involve the family, and focus on behavioural therapy as well as dietary and physical activity patterns. LiGHT is intended to be engaging and fun, provide virtual and tangible rewards, and interact with participants multiple times per day. In addition, it will feature a mobile social support network and interaction with a live coach with specialized training in motivational interviewing to support youth/families in changing their health behaviours through messaging and phone calls.
Study NCT02032433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended-Release Naltrexone
Description: Extended-Release Naltrexone (Vivitrol®)
Study NCT02032433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine-Naloxone
Description: Buprenorphine-Naloxone (Suboxone®)
Study NCT00493701 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: High Fat Diet
Description: Daily eating
Study NCT00493701 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low Fat Diet
Description: Life style eating habits
Study NCT02205281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The intervention is a multi-component program designed to prevent excessive gestational weight gain in overweight and obese women and to promote weight loss in their non-pregnant overweight and obese partners through modifications of diet, exercise, and behavioral strategies during pregnancy.
Study NCT01454037 — intervention group
Intervention type: PROCEDURE
Intervention: Prostate cryotherapy
Description: cryoablate the prostate
Study NCT01454037 — intervention group
Intervention type: PROCEDURE
Intervention: Radical prostatectomy
Description: Remove prostate
Study NCT01454037 — intervention group
Intervention type: PROCEDURE
Intervention: Radiation
Description: Radiate prostate
Study NCT04120116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX-322 (One Dose)
Description: Patients will receive one dose of FX-322.
Study NCT04120116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX-322 (Two Doses)
Description: Patients will receive two doses of FX-322.
Study NCT04120116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX-322 (Four Doses)
Description: Patients will receive four doses of FX-322.
Study NCT04120116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive Placebo.
Study NCT04120116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive Placebo.
Study NCT03410693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877)
Description: Rogaratinib administered as oral (p.o.) tablets twice daily (b.i.d.) continuously
Study NCT03410693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy as taxane (docetaxel or paclitaxel) or vinflunine administered through intravenous (i.v.) infusion every 3 weeks (on day 1 of a 21-day cycle) The choice of the chemotherapy is at the discretion of the investigator, taking into consideration the status of the authorization or treatment guidelines in the given country.
Study NCT04188613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous tracheostomy
Description: Age, gender, height, BMI, ASA scores, presence and type of additional diseases, tracheostomy day, pre- and post-procedure blood gas analysis, duration of procedure, duration of anesthesia, complications during the procedure (bleeding , desaturation, accidental extubation, malposition, bradycardia, hypotension, etc.) will be recorded from intensive care follow-up. Patients will be observed for mortality in the first 30 days after the procedure. Mortality results will be recorded.
Study NCT04188613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous tracheostomy
Description: Age, gender, height, BMI, ASA scores, presence and type of additional diseases, tracheostomy day, pre- and post-procedure blood gas analysis, duration of procedure, duration of anesthesia, complications during the procedure (bleeding , desaturation, accidental extubation, malposition, bradycardia, hypotension, etc.) will be recorded from intensive care follow-up. Patients will be observed for mortality in the first 30 days after the procedure. Mortality results will be recorded.
Study NCT02267018 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drager VN500 Ventilator
Description: This ventilator is capable of providing both nCPAP and NIHFV support.
Study NCT05252299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rolling Fresher Group
Description: The use of telemedicine to provide remote CSS installation instruction via audio and visual input by a Certified child passenger safety technician (CPST)
Study NCT03373188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Undergo therapeutic conventional surgery
Study NCT02406911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: After randomization, each group will be treated as assigned dose of ticagrelor (ticagrelor 90mg once a day or 90mg twice a day) for 14 days. After 1 week wash-out period, cross-over study will be performed
Study NCT02406911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: After randomization, each group will be treated as assigned dose of ticagrelor (ticagrelor 90mg once a day or 90mg twice a day) for 14 days. After 1 week wash-out period, cross-over study will be performed
Study NCT04709445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ICG-NIRF Imaging plus ingress and egress analysis
Description: intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) before and after anastomosis formation, postoperative analysis of ingress and egress for specific regions of interest
Study NCT00532688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 28 days of oral n-acetylcysteine (500mg bd)(in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
Study NCT00532688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcysteine
Description: 28 days of oral n-acetylcysteine (500mg bd)(in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
Study NCT01285934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: All participants randomized to the transplant arm wil undergo Autologous Hematopoietic Stem Cell Transplantation
Study NCT01285934 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: intensive insulin therapy
Description: The control arm will be either CSII via an insulin pump or intensive subcutaneous insulin therapy with multiple insulin injections (at least 4/day) utilizing a long acting background insulin and pre-meal rapid acting insulin.
Study NCT03828331 — intervention group
Intervention type: OTHER
Intervention: Prosthetic/Bicycle Configuration
Description: The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects ride using an initial bike fit and three taller pylon lengths (PL) for the affected leg (AL) in increments of 6.8 mm using a pedal attachment position (PAP) beneath the prosthetic forefoot. Then, using the optimal (most efficient) PL, the investigators will measure the biomechanics and metabolic rates while subjects ride using three shorter crank arm lengths (CALs) for the AL in decrements of 6.8 mm using a PAP beneath the prosthetic forefoot. On Day 2, the investigators will repeat the protocol of Day 1, but have riders use a PAP beneath the pylon for their AL.
Study NCT04042324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
Study NCT04042324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.
Study NCT05511571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical neural stimulation (TENS)
Description: The TENS group: TENS application was implemented by the researchers in the patient room. The conventional TENS application took 30 minutes per session. The application continued until frequency reached 100 Hz, the pulse width reached 100 μs, and the current impedance reached a point where the women felt needling or tingling according to their tolerance. Before the application, the women were asked to lie in a supine position, and the area/skin where TENS would be applied was cleaned and dried. Two electrodes of TENS were placed 2 cm above the cesarean incision, and the other two electrodes 2 cm below the incision. The women were allowed to rest during the application, and they were accompanied by the researcher. A total of five TENS sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held.